For a frequent poster here, suprised you're not aware that IMGN's presentations are later today!
IMGN901 Oral Presentation
•Title: “Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) In Combination with Lenalidomide (Len) and Dexamethasone (Dex) In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)” (Abstract #728).
•When/where: Dec. 10 at 4:45 pm ET in the Thomas Murphy Ballroom 2-3 (Session #653).
BT-062 Poster Presentation
•Title: “BT062, An Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity” (Abstract #4042).
•When/where: Dec. 10 from 6:00-8:00 pm ET in Hall B1-B2 (Session #653; Poster III).
OK, it's past 4:45, still no PR, I guess there was nothing new and material presented. So, again another 2 significant conferences pass and IMGN has nothing new and material to present. Not very impressive. Dan might be able to hype up some short term trading activity tonight on Cramer's MM, but that is not what IMGN needs, we need real progress, or new deals and less dilution going forward.
thanks, I noticed lots of news from other oncology companies over the weekend, SGEN in particular. Also, Roche announced Pertuzumab news at the SABCS and MabThera developments at ASH, no new data on TDM-1.
901 has so far not showed any meaningful data, but oral presentation may signal a change. Adding a few months of survival, or a few months of delayed pregression and a lot of cost simply does not cut it anymore, so I hope they can show some real results, PR's and CR's. If so, we can get excited and price will increase.